Our Pipeline
Currently, two Inhibrx programs are in clinical trials for the treatment of various cancers.
The Candidates
Phase 1
Phase 2
Phase 3
Oncology
Ozekibart (INBRX-109) is a tetravalent agonist that targets human death receptor 5 (DR5) to induce tumor-selective programmed cell death. Based on Inhibrx’s single-domain antibody platform, ozekibart (INBRX-109) is precisely engineered to achieve an optimal balance of agonism and safety.
Phase 1 clinical trials are enrolling patients with Ewing Sarcoma.
Learn more Phase 1 Trial
INBRX-106
Hexavalent OX40 Agonist
Oncology
INBRX-106 is a novel, hexavalent OX40 agonist designed to promote hyperclustering of OX40, resulting in more potent activation of the OX40 costimulatory pathway and more robust antitumor activity than traditional Fc crosslinking–dependent OX40 bivalent therapeutic antibodies.
Learn more Phase 2/3 Trial Phase 1/2 Trial